Skip to main content
Erschienen in: PharmacoEconomics 3/2003

01.02.2003 | Current Opinion

NICE Methodological Guidelines and Decision Making in the National Health Service in England and Wales

verfasst von: Dr Amiram Gafni, Stephen Birch

Erschienen in: PharmacoEconomics | Ausgabe 3/2003

Einloggen, um Zugang zu erhalten

Abstract

The National Institute for Clinical Excellence (NICE) responds to requests by the Department of Health for guidance on the use of selected new and established technologies in the National Health Service (NHS) in England and Wales. This paper asks whether the NICE methodological guidelines help NHS decision makers meet the objectives of maximum health improvements from NHS resources and an equitable availability of technologies. The analytical basis of the guidelines is a comparison of the costs and consequences of new and existing methods of dealing with particular conditions using the incremental cost-effectiveness ratio. We explain why information on the costs and consequences of a particular technology in isolation is insufficient to address issues of efficiency of resource use. We argue that to increase efficiency, decision makers need information on opportunity costs. We show that in the absence of such information decision makers cannot identify the efficient use of resources. Finally we argue that economics provides valid methods for identifying the maximisation of health improvements for a given allocation of resources and we describe an alternative practical approach to this problem. Drawing on the experience of Ontario, Canada where an approach similar to that proposed by NICE has been in use for almost a decade, and recent reports about the consequences of NICE decisions to date, we conclude that instead of increasing the efficiency or equity of the use of NHS resources, NICE methodological guidelines may lead to: (i) uncontrolled increases in NHS expenditures without evidence of any increase in total health improvements; (ii) increased inequities in the availability of services; and (iii) concerns about the sustainability of public funding for new technologies.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat House of Commons’ Select Committee. Health: National Institute for Clinical Excellence. London: Her Majesty’s Stationery Office, 2002 House of Commons’ Select Committee. Health: National Institute for Clinical Excellence. London: Her Majesty’s Stationery Office, 2002
2.
Zurück zum Zitat National Institute for Clinical Excellence. Technical guidance for manufactures and sponsors on making a submission to a technology appraisal. London: National Institute for Clinical Excellence, 2001 National Institute for Clinical Excellence. Technical guidance for manufactures and sponsors on making a submission to a technology appraisal. London: National Institute for Clinical Excellence, 2001
3.
Zurück zum Zitat Birch S, Gafni A. On being NICE in the UK: guidelines for technology appraisal for the NHS in England and Wales. Health Econ 2002; 11: 185–91PubMedCrossRef Birch S, Gafni A. On being NICE in the UK: guidelines for technology appraisal for the NHS in England and Wales. Health Econ 2002; 11: 185–91PubMedCrossRef
4.
5.
Zurück zum Zitat Sculpher H, Drummond M, O’Brien B. Effectiveness, efficiency and NICE. BMJ 2001; 322: 943–4PubMedCrossRef Sculpher H, Drummond M, O’Brien B. Effectiveness, efficiency and NICE. BMJ 2001; 322: 943–4PubMedCrossRef
6.
Zurück zum Zitat Cookson R, McDaid D, Maynard A. Wrong SIGN, NICE mess: is national guidance distorting allocation of resources? BMJ 2001; 323: 743–5PubMedCrossRef Cookson R, McDaid D, Maynard A. Wrong SIGN, NICE mess: is national guidance distorting allocation of resources? BMJ 2001; 323: 743–5PubMedCrossRef
7.
Zurück zum Zitat Weinstein HC, Stason WB. Foundation of cost-effectiveness analysis for health and medical practices. N Engl J Med 1977; 296: 716–21PubMedCrossRef Weinstein HC, Stason WB. Foundation of cost-effectiveness analysis for health and medical practices. N Engl J Med 1977; 296: 716–21PubMedCrossRef
8.
Zurück zum Zitat Taylor R. Generating national guidance: a nice model? Paper presented at the Fifth International Conference on Strategic Issues in Health Care Management Policy, Finance and Performance in Health Care; 2002 Apr 11–13; St Andrews, Scotland Taylor R. Generating national guidance: a nice model? Paper presented at the Fifth International Conference on Strategic Issues in Health Care Management Policy, Finance and Performance in Health Care; 2002 Apr 11–13; St Andrews, Scotland
9.
Zurück zum Zitat Weinstein M, Zeckhauser R. Critical ratios and efficient allocation. J Public Econ 1973; 2: 147–57CrossRef Weinstein M, Zeckhauser R. Critical ratios and efficient allocation. J Public Econ 1973; 2: 147–57CrossRef
10.
Zurück zum Zitat Birch S, Gafni A. Cost-effectiveness/utility analysis: do current decision rules lead us to where we want to be? J Health Econ 1992; 11: 279–96PubMedCrossRef Birch S, Gafni A. Cost-effectiveness/utility analysis: do current decision rules lead us to where we want to be? J Health Econ 1992; 11: 279–96PubMedCrossRef
11.
Zurück zum Zitat Birch S, Gafni A. Changing the problem to fit the solution: Johannesson and Weinstein’s (mis)application of economics to real world problems. J Health Econ 1993; 12: 469–76PubMedCrossRef Birch S, Gafni A. Changing the problem to fit the solution: Johannesson and Weinstein’s (mis)application of economics to real world problems. J Health Econ 1993; 12: 469–76PubMedCrossRef
12.
Zurück zum Zitat Laupacis A, Feeny D, Detsky A, et al. How attractive does a new technology have to be to warrant adoption and utilization?: tentative guidelines for using clinical and economic evaluations. CMAJ 1992; 146: 473–81PubMed Laupacis A, Feeny D, Detsky A, et al. How attractive does a new technology have to be to warrant adoption and utilization?: tentative guidelines for using clinical and economic evaluations. CMAJ 1992; 146: 473–81PubMed
13.
Zurück zum Zitat Gafni A, Birch S. Guidelines for the adoption of new technologies: a prescription for uncontrolled growth in expenditures and how to avoid the problem. CMAJ 1993; 148: 913–7PubMed Gafni A, Birch S. Guidelines for the adoption of new technologies: a prescription for uncontrolled growth in expenditures and how to avoid the problem. CMAJ 1993; 148: 913–7PubMed
14.
Zurück zum Zitat Laupacis A. Inclusion of drugs in provincial drug benefit programs: who is making these decisions, and are they the right ones? CMAJ 2002; 166: 44–7PubMed Laupacis A. Inclusion of drugs in provincial drug benefit programs: who is making these decisions, and are they the right ones? CMAJ 2002; 166: 44–7PubMed
15.
Zurück zum Zitat Williams A. The economic role of ‘health indicators’. In: Teeling Smith G, editor. Measuring the social benefits of medicine. London: Office of Health Economics, 1983 Williams A. The economic role of ‘health indicators’. In: Teeling Smith G, editor. Measuring the social benefits of medicine. London: Office of Health Economics, 1983
16.
Zurück zum Zitat Sendi P, Gafni A, Birsh S. Opportunity costs and uncertainty in the economic evaluation of health care interventions. Health Econ 2002; 11: 23–31PubMedCrossRef Sendi P, Gafni A, Birsh S. Opportunity costs and uncertainty in the economic evaluation of health care interventions. Health Econ 2002; 11: 23–31PubMedCrossRef
17.
Zurück zum Zitat Naylor CD. Cost-effectiveness analysis: are the outputs worth the inputs? ACP Journal Club 1996; 124: A12–4PubMed Naylor CD. Cost-effectiveness analysis: are the outputs worth the inputs? ACP Journal Club 1996; 124: A12–4PubMed
18.
Zurück zum Zitat Culyer AJ. Health, economics and health economics. In: van der Gaaf J, Perlman M, editors. Health, economics and health economics. Amsterdam: North-Holland Publishing Company, 1981: 3–11 Culyer AJ. Health, economics and health economics. In: van der Gaaf J, Perlman M, editors. Health, economics and health economics. Amsterdam: North-Holland Publishing Company, 1981: 3–11
19.
Zurück zum Zitat Maynard A, Sheldon T. Health economics: has it fulfilled its potential? In: Maynard A, Chalmers I, editors. Non-random reflection on health services research. London: BMJ Press, 1997 Maynard A, Sheldon T. Health economics: has it fulfilled its potential? In: Maynard A, Chalmers I, editors. Non-random reflection on health services research. London: BMJ Press, 1997
20.
Zurück zum Zitat Burk K. NICE may fail to stop “postcode prescribing”, MPs told. BMJ 2002; 324: 191CrossRef Burk K. NICE may fail to stop “postcode prescribing”, MPs told. BMJ 2002; 324: 191CrossRef
Metadaten
Titel
NICE Methodological Guidelines and Decision Making in the National Health Service in England and Wales
verfasst von
Dr Amiram Gafni
Stephen Birch
Publikationsdatum
01.02.2003
Verlag
Springer International Publishing
Erschienen in
PharmacoEconomics / Ausgabe 3/2003
Print ISSN: 1170-7690
Elektronische ISSN: 1179-2027
DOI
https://doi.org/10.2165/00019053-200321030-00001

Weitere Artikel der Ausgabe 3/2003

PharmacoEconomics 3/2003 Zur Ausgabe